Supplementary Table S9 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target

Supplementary Table S9 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target

<p>Table S9 shows the (a) differentially expressed transcripts and (b) altered pathways as identified by GSEA from the ELAVL1 knockdown human primary AML RNA-sequencing data set.</p>

保存先:

書誌詳細
第一著者:	Ana Vujovic (15207479) (author)
その他の著者:	Laura de Rooij (15207482) (author), Ava Keyvani Chahi (15207485) (author), He Tian Chen (15207488) (author), Brian A. Yee (15207491) (author), Sampath K. Loganathan (15121740) (author), Lina Liu (15207494) (author), Derek C.H. Chan (15207497) (author), Amanda Tajik (15207500) (author), Emily Tsao (15207503) (author), Steven Moreira (14937143) (author), Pratik Joshi (15207506) (author), Joshua Xu (15207509) (author), Nicholas Wong (15207512) (author), Zaldy Balde (15207515) (author), Soheil Jahangiri (15207518) (author), Sasan Zandi (15207521) (author), Stefan Aigner (15207524) (author), John E. Dick (14937554) (author), Mark D. Minden (14961936) (author), Daniel Schramek (15121764) (author), Gene W. Yeo (15207527) (author), Kristin J. Hope (15207530) (author)
出版事項:	2025
主題:	Cancer Cancer Biology Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Drug Targets Oncoprotein & tumor suppressor drug targets Gene Regulation Posttranscriptional and translational control Hematological Cancers Leukemias Oncogenes & Tumor Suppressors Oncogenes Preclinical Models Xenograft models Small Molecule Agents Stem Cell Biology Cancer stem cells Hematopoiesis
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Supplementary Table S1 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplementary Table S2 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplementary Table S3 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplementary Table S4 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplementary Table S5 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplementary Table S6 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplementary Table S7 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplementary Table S8 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
著者:: Amir T. Fathi (15313195)
出版事項: (2025)

Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
著者:: Amir T. Fathi (15313195)
出版事項: (2025)

Supplementary Tables S1-14 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations
著者:: Smruthy Sivakumar (15053536)
出版事項: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
著者:: Long Jiang (14956159)
出版事項: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
著者:: Long Jiang (14956159)
出版事項: (2025)

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
著者:: Long Jiang (14956159)
出版事項: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
著者:: Anne-Florence Blandin (15056366)
出版事項: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
著者:: Anne-Florence Blandin (15056366)
出版事項: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
著者:: Anne-Florence Blandin (15056366)
出版事項: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
著者:: Anne-Florence Blandin (15056366)
出版事項: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
著者:: Anne-Florence Blandin (15056366)
出版事項: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
著者:: Anne-Florence Blandin (15056366)
出版事項: (2025)

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
著者:: Anne-Florence Blandin (15056366)
出版事項: (2025)

Table S1 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
著者:: Yun-Guang Hong (14960966)
出版事項: (2025)

Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
著者:: Yun-Guang Hong (14960966)
出版事項: (2025)

Table S3 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
著者:: Yun-Guang Hong (14960966)
出版事項: (2025)

Table S4 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
著者:: Yun-Guang Hong (14960966)
出版事項: (2025)

Table S5 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
著者:: Yun-Guang Hong (14960966)
出版事項: (2025)

Table S6 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
著者:: Yun-Guang Hong (14960966)
出版事項: (2025)

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
著者:: Feng Wang (44414)
出版事項: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
著者:: Feng Wang (44414)
出版事項: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
著者:: Feng Wang (44414)
出版事項: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
著者:: Feng Wang (44414)
出版事項: (2025)

Supplementary Tables S3-5 from Activation of the cGAS/STING Axis in Genome-Damaged Hematopoietic Cells Does Not Impact Blood Cell Formation or Leukemogenesis
著者:: Nicole Dressel (16918215)
出版事項: (2025)

Cannot write session to /tmp/vufind_sessions/sess_mfv2ght18h4sdhs8g6c62nqsoi